N@N

ArQule, Inc. to Present at Stifel Nicolaus and UBS Conferences

_{//health-fitness.news-articles.net/content/2010/ .. sent-at-stifel-nicolaus-and-ubs-conferences.html}
^{Published in Health and Fitness on Friday, September 10th 2010 at 5:45 GMT by Market Wire}  

WOBURN, Mass.--([ BUSINESS WIRE ])--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2010 Stifel Nicolaus Healthcare Conference on September 17, 2010 at 11:30 a.m. and at the UBS Global Life Sciences Conference on September 20, 2010 at 12:30 p.m.

The presentations will be web cast live and may be accessed through the investor relations section of the Companya�s website, [ http://www.arqule.com ]. The Stifel Nicolaus conference (September 15-17, 2010) will be held at the Four Seasons Hotel, Boston. The UBS conference (September 20-22, 2010) will be held at the Grand Hyatt Hotel, New York.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companya�s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQulea�s lead product, in Phase 2 and upcoming Phase 3 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Companya�s pre-clinical pipeline includes a compound designed to inhibit the B-RAF kinase. ArQulea�s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIPa"), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. These include a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR).